Melanotan I vs α-MSH

Alpha-MSH is the natural 13-amino-acid melanocortin hormone. Melanotan-1 changes two residues to make it far more stable and potent at MC1R.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Melanotan I

A linear α-MSH analogue that selectively activates MC1R, approved (as an implant) to prevent phototoxicity in erythropoietic protoporphyria.

BEST STUDIED FOR

Melanocortin

Read the cited profile →

🧪

	Melanotan I	α-MSH
The key difference	Stabilised synthetic analogue	Native, short-lived hormone
Class	Melanocortin	Melanocortin
Mechanism	Afamelanotide binds the melanocortin-1 receptor on melanocytes, increasing eumelanin production.	α-MSH acts across melanocortin receptors: MC1R on melanocytes (pigmentation, photoprotection), MC4R in the hypothalamus (appetite suppression) and immune-cell receptors that mediate anti-inflammatory effects.
Status	Approved in the EU (2014) and US (2019) as a subcutaneous implant for erythropoietic protoporphyria (EPP). Unregulated injectable "melanotan" products are a separate, unapproved market.	Endogenous hormone and research tool; studied in inflammation, neurodegeneration and melanoma biology.
Reported safety signals	In the EPP trials the implant was well tolerated; dermatology reviews warn about unregulated use of melanotan products and the need for mole surveillance.	Natural α-MSH is short-lived; safety concerns in the literature centre on its synthetic, unregulated analogues.
A key study	Randomised trials measured pain-free sunlight exposure and safety with afamelanotide implants in EPP. (N Engl J Med 2015, PMID 26132941)	Reviews α-MSH as the most potent natural melanotropic peptide, acting through widely expressed melanocortin receptors. (Peptides 2006, PMID 16274844)

Alpha-MSH for physiology; melanotan-1 for a drug-like MC1R agonist with clinical data. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Melanotan I] Afamelanotide for Erythropoietic Protoporphyria — N Engl J Med 2015. PMID 26132941
[Melanotan I] Afamelanotide: A Review in Erythropoietic Protoporphyria — Am J Clin Dermatol 2016. PMID 26979527
[Melanotan I] Afamelanotide in protoporphyria and other skin diseases: a review — Postepy Dermatol Alergol 2024. PMID 38784937
[α-MSH] alpha-Melanocyte stimulating hormone, inflammation and human melanoma — Peptides 2006. PMID 16274844
[α-MSH] Alpha-Melanocyte-Stimulating Hormone-Mediated Appetite Regulation in the Central Nervous System — Neuroendocrinology 2023. PMID 37094550
[α-MSH] Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model — Sci Rep 2020. PMID 32350353

FREQUENTLY ASKED

What is the difference between Melanotan I and α-MSH?

Alpha-MSH is the natural 13-amino-acid melanocortin hormone. Melanotan-1 changes two residues to make it far more stable and potent at MC1R.

What is the regulatory status of Melanotan I and α-MSH?

Melanotan I: Approved in the EU (2014) and US (2019) as a subcutaneous implant for erythropoietic protoporphyria (EPP). Unregulated injectable "melanotan" products are a separate, unapproved market. α-MSH: Endogenous hormone and research tool; studied in inflammation, neurodegeneration and melanoma biology.

What safety signals have been reported?

Melanotan I: In the EPP trials the implant was well tolerated; dermatology reviews warn about unregulated use of melanotan products and the need for mole surveillance. α-MSH: Natural α-MSH is short-lived; safety concerns in the literature centre on its synthetic, unregulated analogues.

Which studies is this comparison based on?

For Melanotan I: “Afamelanotide for Erythropoietic Protoporphyria” (PMID 26132941); “Afamelanotide: A Review in Erythropoietic Protoporphyria” (PMID 26979527); “Afamelanotide in protoporphyria and other skin diseases: a review” (PMID 38784937). For α-MSH: “alpha-Melanocyte stimulating hormone, inflammation and human melanoma” (PMID 16274844); “Alpha-Melanocyte-Stimulating Hormone-Mediated Appetite Regulation in the Central Nervous System” (PMID 37094550); “Anti-inflammatory effects of α-MSH through p-CREB expression in sarcoidosis like granuloma model” (PMID 32350353).